Presenting Phase 2 Trial Efficacy Data to Biotech Venture Capitalists
Biotech VCs scrutinize $p$-values, hazard ratios, and adverse event profiles. Here is how founders present trial endpoints with scientific rigor.
Vishal VermaCTO & Co-Founder, Dehurdle
May 13, 20254 min read
The Primary Endpoint Delivery Script
Recommended Spoken Script
"In our double-blind, randomized Phase 2 trial of 120 patients, our small molecule met its primary endpoint with a statistically significant 42% reduction in tumor volume ($p < 0.001$) versus standard of care. Treatment-related Grade 3 adverse events remained below 4%, providing a clean therapeutic window for our Phase 3 FDA registrational trial."
The 2-Minute Practice Drill
2-Minute Spoken Drill
The 2-Minute Practice Drill
Practice your biotech investor pitch in Dehurdle.
Follow Dehurdle on Google
Add Dehurdle to your Google Preferred Sources to see our playbooks in your AI Overviews and Google Search.